With 0.64 million shares changed hands, the volume of the stock remained heavier than its average volume of 89610.0 shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $4.234 whereas the lowest price it dropped to was $3.47. The 52-week range on BNGO shows that it touched its highest point at $33.72 and its lowest point at $2.68 during that stretch. It currently has a 1-year price target of $9.50. Beta for the stock currently stands at 2.24.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BNGO was up-trending over the past week, with a rise of 28.66%, but this was up by 18.00% over a month. Three-month performance surged to 14.09% while six-month performance fell -22.66%. The stock lost -76.13% in the past year, while it has lost -87.64% so far this year. A look at the trailing 12-month EPS for BNGO yields -44.85 with Next year EPS estimates of -4.14. For the next quarter, that number is -2.02. This implies an EPS growth rate of 91.84% for this year and 42.41% for next year. EPS is expected to grow by 75.99% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 40.63%.
Float and Shares Shorts:
At present, 4.68 million BNGO shares are outstanding with a float of 4.66 million shares on hand for trading. On 2025-07-31, short shares totaled 0.33 million, which was 989.0000499999999 higher than short shares on 1751241600. In addition to Dr. Robert Erik Holmlin M.B.A., Ph.D. as the firm’s President, CEO, CFO & Director, Mr. Mark Oldakowski serves as its Chief Operating Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, BNGO reported revenue of $6733000.0 and operating income of -$7800000.0. The EBITDA in the recently reported quarter was -$4343000.0 and diluted EPS was -$1.99.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BNGO since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BNGO analysts setting a high price target of 11.0 and a low target of 8.0, the average target price over the next 12 months is 9.5. Based on these targets, BNGO could surge 166.34% to reach the target high and rise by 93.7% to reach the target low. Reaching the average price target will result in a growth of 130.02% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$74.77615 being high and -$86.2961 being low. For BNGO, this leads to a yearly average estimate of -$80.1. The surprise factor in the prior quarter was -$3.02. Based on analyst estimates, the high estimate for the next quarter is -$2.14 and the low estimate is -$2.14. The average estimate for the next quarter is thus -$2.14.
